Guidelines to PET measurements of the target occupancy in the brain for drug development

Akihiro Takano; Andrea Varrone; Balazs Gulyas; Piero Salvadori; Antony Gee; Albert Windhorst; Johnny Vercouillie; Guy Bormans; Adriaan A. Lammertsma; Christer Halldin

doi:https://doi.org/10.1007/s00259-016-3476-4

Guidelines to PET measurements of the target occupancy in the brain for drug development

Akihiro Takano, Andrea Varrone, Balazs Gulyas, Piero Salvadori, Antony Gee, Albert Windhorst, Johnny Vercouillie, Guy Bormans, Adriaan A. Lammertsma, Christer Halldin

Research output: Contribution to journal › Article › Academic › peer-review

25 Citations (Scopus)

Abstract

This guideline summarizes the current view of the European Association of Nuclear Medicine Drug Development Committee. The purpose of this guideline is to guarantee a high standard of PET studies that are aimed at measuring target occupancy in the brain within the framework of development programs of drugs that act within the central nervous system (CNS drugs). This guideline is intended to present information specifically adapted to European practice. The information provided should be applied within the context of local conditions and regulations.

Original language	English
Pages (from-to)	2255-2262
Journal	European journal of nuclear medicine and molecular imaging
Volume	43
Issue number	12
DOIs	https://doi.org/10.1007/s00259-016-3476-4
Publication status	Published - Nov 2016

Keywords

Drug development
Positron emission tomography
Target occupancy

Access to Document

https://doi.org/10.1007/s00259-016-3476-4

Cite this

@article{844edf33f8ef4ad79f6b3c14a5863735,

title = "Guidelines to PET measurements of the target occupancy in the brain for drug development",

abstract = "This guideline summarizes the current view of the European Association of Nuclear Medicine Drug Development Committee. The purpose of this guideline is to guarantee a high standard of PET studies that are aimed at measuring target occupancy in the brain within the framework of development programs of drugs that act within the central nervous system (CNS drugs). This guideline is intended to present information specifically adapted to European practice. The information provided should be applied within the context of local conditions and regulations.",

keywords = "Drug development, Positron emission tomography, Target occupancy",

author = "Akihiro Takano and Andrea Varrone and Balazs Gulyas and Piero Salvadori and Antony Gee and Albert Windhorst and Johnny Vercouillie and Guy Bormans and Lammertsma, {Adriaan A.} and Christer Halldin",

year = "2016",

month = nov,

doi = "https://doi.org/10.1007/s00259-016-3476-4",

language = "English",

volume = "43",

pages = "2255--2262",

journal = "European journal of nuclear medicine and molecular imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "12",

}

TY - JOUR

T1 - Guidelines to PET measurements of the target occupancy in the brain for drug development

AU - Takano, Akihiro

AU - Varrone, Andrea

AU - Gulyas, Balazs

AU - Salvadori, Piero

AU - Gee, Antony

AU - Windhorst, Albert

AU - Vercouillie, Johnny

AU - Bormans, Guy

AU - Lammertsma, Adriaan A.

AU - Halldin, Christer

PY - 2016/11

Y1 - 2016/11

N2 - This guideline summarizes the current view of the European Association of Nuclear Medicine Drug Development Committee. The purpose of this guideline is to guarantee a high standard of PET studies that are aimed at measuring target occupancy in the brain within the framework of development programs of drugs that act within the central nervous system (CNS drugs). This guideline is intended to present information specifically adapted to European practice. The information provided should be applied within the context of local conditions and regulations.

AB - This guideline summarizes the current view of the European Association of Nuclear Medicine Drug Development Committee. The purpose of this guideline is to guarantee a high standard of PET studies that are aimed at measuring target occupancy in the brain within the framework of development programs of drugs that act within the central nervous system (CNS drugs). This guideline is intended to present information specifically adapted to European practice. The information provided should be applied within the context of local conditions and regulations.

KW - Drug development

KW - Positron emission tomography

KW - Target occupancy

U2 - https://doi.org/10.1007/s00259-016-3476-4

DO - https://doi.org/10.1007/s00259-016-3476-4

M3 - Article

C2 - 27514528

SN - 1619-7070

VL - 43

SP - 2255

EP - 2262

JO - European journal of nuclear medicine and molecular imaging

JF - European journal of nuclear medicine and molecular imaging

IS - 12

ER -